Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience-Reference-Cited by-同舟云学术

Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience

Author:

Kuo Christopher¹,Kent Paul M.¹,Logan Antonio D.¹,Tamulonis Karen B.¹,Dalton Kristen L.²,Batus Marta³,Fernandez Karen⁴,Mcfall Rebecca E.⁵

Affiliation:

1. Division of Pediatric Hematology/Oncology; Department of Pediatrics; Rush University Medical Center; Chicago Illinois

2. Department of Pediatrics; The Children's Hospital of Philadelphia; Philadelphia Pennsylvania

3. Division of Medical Oncology; Department of Internal Medicine; Rush University Medical Center; Chicago Illinois

4. Division of Hematology/Oncology; Department of Pediatrics; University of Illinois College of Medicine; Peoria Illinois

5. Division of Hematology/Oncology; Department of Pediatrics; Advocate Christ Medical Center; Oak Lawn Illinois

Funder

Amanda Sarmiento Memorial Fund.

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

Reference48 articles.

1. Epidemiology and therapies for metastatic sarcoma;Amankwah;Clin Epidemiol,2013

3. Recent advances in osteosarcoma;Botter;Curr Opin Pharmacol,2014

5. Gemcitabine: preclinical pharmacology and mechanisms of action;Plunkett;Semin Oncol,1996

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献